Form 4: Aprea Therapeutics CFO Buys Warrants in Private Placement

Aprea Therapeutics' Senior VP and CFO, John P. Hamill, acquired pre-funded and common warrants in a private placement, signaling insider confidence.

Summary

• John P. Hamill, Senior VP, CFO, and Principal Financial & Accounting Officer of Aprea Therapeutics, Inc. (APRE), acquired derivative securities.
• The transaction involved the purchase of 30,978 pre-funded warrants and 30,978 common warrants in a private placement that closed on March 31, 2026.
• The pre-funded warrants allow the purchase of common stock at an exercise price of $0.001 per share, with a purchase price of $0.808 per warrant (less the exercise price).
• The common warrants allow the purchase of common stock at an exercise price of $0.683 per share.
• Both types of warrants are immediately exercisable, subject to beneficial ownership limitations.
• The common warrants expire on the earlier of December 31, 2029, or 30 calendar days after the corresponding pre-funded warrant is exercised.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. The acquisition of warrants by a key executive like the CFO demonstrates significant confidence in the company's future performance and potential for stock appreciation.

Positives

• The acquisition of warrants by a senior executive (CFO) signals strong insider confidence in the company's future prospects.
• The pre-funded warrants have a very low exercise price of $0.001, indicating a significant potential upside for the holder if the stock price increases.

Negatives

• The future exercise of these warrants could lead to dilution for existing shareholders, although the number of shares is relatively small in this instance.

Risks

• The exercise of warrants is subject to a beneficial ownership limitation, preventing the holder from exceeding 4.99% of outstanding common stock or 9.99% of combined voting power.
• The value of the warrants is dependent on the future market price of Aprea Therapeutics' common stock, exposing the holder to market risk.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the terms and conditions of the acquired warrants, such as their exercisability and expiration dates.

Management Comments

• John P. Hamill, as the reporting person, entered into a securities purchase agreement with the Issuer, indicating a direct investment decision by a key executive.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a CFO, is often interpreted by the market as a positive signal, suggesting that management believes the company's stock is undervalued or expects positive developments. This action aligns with a broader trend where executives invest in their own companies to demonstrate confidence.

Comparison to Industry Standards

• Insider purchases of warrants are a common mechanism for executives to increase their stake and align interests with shareholders, similar to practices seen across the biotechnology and pharmaceutical sectors.
• The beneficial ownership limitations (4.99% and 9.99%) are standard provisions in private placements to avoid triggering certain regulatory reporting requirements or change of control provisions.

Related Party Transactions

• The transaction involves John P. Hamill, a Senior VP, CFO, and Principal Financial & Accounting Officer of Aprea Therapeutics, Inc., acquiring securities directly from the company in a private placement, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The future exercise of these warrants could lead to a slight increase in the number of outstanding shares, potentially causing minor dilution for existing shareholders.

Next Steps

• The reporting person may choose to exercise the pre-funded warrants and common warrants at any time, subject to the beneficial ownership limitations.

Key Dates

Recommendation

The insider purchase by the CFO, John P. Hamill, is a strong bullish signal. Executives typically buy shares or warrants when they believe the company's stock is undervalued or poised for significant growth. This direct investment aligns management's interests with shareholders and suggests positive internal outlooks not yet fully reflected in the market price, making it an attractive entry point for investors.

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Warrants, Private Placement, CFO, Stock Acquisition, Beneficial Ownership, Securities Purchase Agreement